Aegle Therapeutics Corporation is a privately held, clinical-stage regenerative medicine company developing extracellular vesicle (EV) therapy — a cell-free therapeutic composite of EVs, including exosomes, isolated from allogeneic bone marrow-derived mesenchymal stem cells using its proprietary EV harvesting technology. Its lead candidate, AGLE-102, is in a Phase 1/2 clinical study for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other severe dermatological disorders with significant unmet medical need. The company publishes a seven-page WordPress marketing site and no developer program, API, SDK or machine-readable specification of any kind.
Aegle Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Regenerative Medicine, and Clinical Stage.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: aegle-therapeutics
name: Aegle Therapeutics
description: Aegle Therapeutics Corporation is a privately held, clinical-stage regenerative medicine company developing extracellular
vesicle (EV) therapy — a cell-free therapeutic composite of EVs, including exosomes, isolated from allogeneic bone marrow-derived
mesenchymal stem cells using its proprietary EV harvesting technology. Its lead candidate, AGLE-102, is in a Phase 1/2 clinical
study for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and other severe dermatological disorders with significant unmet
medical need. The company publishes a seven-page WordPress marketing site and no developer program, API, SDK or machine-readable
specification of any kind.
url: https://raw.githubusercontent.com/api-evangelist/aegle-therapeutics/refs/heads/main/apis.yml
image: https://cdn.aegletherapeutics.com/app/uploads/2023/01/cropped-aegle-icon-1-270x270.png
x-type: company
x-source: harvest:secondary-market
x-harvest-source: https://www.nasdaqprivatemarket.com/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-09'
modified: '2026-09-09'
tags:
- Company
- Biotechnology
- Life Sciences
- Regenerative Medicine
- Clinical Stage
- Pharmaceuticals
- Rare Disease
- Health
position: Producing
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://aegletherapeutics.com/
- type: About
url: https://aegletherapeutics.com/company/
- type: Contact
url: https://aegletherapeutics.com/contact/
- type: Newsroom
url: https://aegletherapeutics.com/news/
- type: PrivacyPolicy
url: https://aegletherapeutics.com/privacy-policy/
- type: LinkedIn
url: https://www.linkedin.com/company/aegletherapeutics
- type: DomainSecurity
url: security/aegle-therapeutics-domain-security.yml
- type: ContentSignal
url: well-known/aegle-therapeutics-robots.txt
- type: LLMsTxt
url: llms/aegle-therapeutics-llms.txt
x-enrichment:
date: '2026-09-09'
status: minimal
artifacts_added: 4
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: Aegle Therapeutics is a clinical-stage extracellular-vesicle drug developer whose entire public surface is a seven-page
WordPress marketing site (home, company, EV therapy, pipeline, news, contact, policies) — its sitemap lists no developer,
API, docs or pricing page, and the only machine-readable endpoint on the domain is the site's own /wp-json/ CMS route,
which returns 401 rest_authentication_error to anonymous callers.
evidence:
- url: https://aegletherapeutics.com/page-sitemap.xml
status: 200
- url: https://aegletherapeutics.com/openapi.json
status: 404
- url: https://aegletherapeutics.com/llms.txt
status: 404
- url: https://aegletherapeutics.com/.well-known/agent-card.json
status: 404
- url: https://aegletherapeutics.com/wp-json/
status: 401
checked: '2026-09-09'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →